Neil Minkoff, MD, CEO, FountainHead HealthCare, discusses the impact that formulary has on both employer and consumer choice in the health insurance exchanges.
Neil Minkoff, MD, CEO, FountainHead HealthCare, discusses the impact that formulary has on both employer and consumer choice in the health insurance exchanges. He says that the industry has reached a point where an estimated 75% to 80% of prescription drug volume is generic. However, there’s less scrutiny of pharmacy benefits in general, as that scrutiny has moved to biotech and specialty.
“The employer and the plan are in a position of needing to offer the appropriate drug to the appropriate patient because it’s become the standard of care, but not being so generous in a benefit that they suffer from adverse selection… and that’s the tight rope that both employers and plans are trying to deal with right now,” he says.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More